Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Vonicog alfa for severe von Willebrand disease. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions People with von Willebrand disease either have a deficiency of a blood protein called von Willebrand factor, or this protein doesn't work properly. This means that their blood cannot clot properly and they are prone to prolonged or excessive bleeding. There are three different types of von Willebrand disease – types 1, 2, and 3. Type 3 is rare and people with this type have very low levels of von Willebrand factor in their blood, or none at all.
Vonicog alfa is a new drug that is given in a drip (directly into a vein). It is being studied to see whether it reduces bleeding in people with severe von Willebrand disease, and that it is safe to use. If vonicog alfa is licensed for use in the UK, it could provide a new treatment for people with severe von Willebrand disease. Indexing Status Subject indexing assigned by CRD MeSH Blood Proteins; Hemorrhage; Humans; Thrombosis; von Willebrand Diseases; von Willebrand Factor Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000752 Date abstract record published 14/06/2016 |